A recombinant interferon (IFN) hybrid has been found to have a broad host-range of activity in an antiviral assay (plaque reduction of vesicular stomatitis virus) and also high efficacy as an antiviral agent in at least 12 different animal cell species. The IFN hybrid consists of amino acids 1 to 60 from HulFN-c~B and amino acids 61 to 166 from HuIFN-c~D. The profile of cross-species activity of the IFN-,B/D hybrid has been compared with that of HulFN-c~F, and of the parents HulFN-c~B and -c~D. When both IFN-c~B and -aD were active in a cell species, the hybrid IFN had comparable or better activity than the more active parental IFN. The hybrid shared a broad cross-species activity with IFN-c~D. However, the IFN-c~B/D hybrid was 10-fold more active on human cells, 30-fold more active on rabbit cells, and 50-fold more active on mouse cells than IFN-~D.
Numerous studies using crude or partially purified mixtures of interferon (IFN) have shown that these preparations usually exert antiviral activity in a defined variety of cell species (for review, see Stewart, 1981) . These studies were refined when recombinant IFN became available, when it was observed that the profile of host-range specificity could vary widely between individual species of IFN (Streuli et al., 1981; Yelverton et al., 1981; . Cross-species efficacy has proved to be a useful biological parameter to discriminate between IFN-c~ hybrids constructed by combining gene fragments of individual species of HulFN-c~. In particular, the spectrum of activity of some IFN-~A/D hybrids is different from that of either parent (Streuli et al., 1981; Rehberg et al., 1982; Weck et al., 1981b) . The construction of human hybrid molecules with high specific activity on unrelated animal species might provide a useful tool for studying the biology of the IFN system in various animal species.
The purpose of this report is to describe the antiviral properties of a recombinant human IFN hybrid which has not only a very broad host-range of activity but also a high efficacy. The hybrid comprises amino acids 1 to 60 from IFN-c~B and amino acids 61 to 166 from IFN-c~D as previously described (Meister et al., 1986) .
The types of recombinant IFN (> 90~ pure) used in this study were produced in yeast, and their final purification involved affinity immunochromatography using monoclonal antibodies. IFN titres calibrated against HulFN-c~ (NIH standard G 023-901-527) on human diploid cells were: IFN-c~B/D hybrid (0.5 x 108 IU/mg), IFN-c~B (2.5 x 108 IU/mg), IFN-c~D (4 x 10 ° IU/mg) and IFN-c~F (0.5 x 108 IU/mg). Whenever possible, the target cells were diploid cells with a finite life span in tissue culture. They were obtained by digestion of tissues with a neutral protease (Dispase, Boehringer-Mannheim) at pH 6.7 in phosphate-buffered saline. All cells were propagated in Eagle's MEM supplemented with 10~o foetal bovine serum and antibiotics. Primary cells and established cell lines were subcultured using a solution of trypsin (1:250) in EDTA (Gibco).
The cross-species activity of IFN was assessed in a sensitive antiviral assay using plaque reduction of vesicular stomatitis virus (VSV) Indiana serotype. The plaque reduction assay is independent of the multiplicity of infection which otherwise affects the apparent degree of 0000-7418 © 1987 SGM protection induced by a fixed concentration of IFN in a yield reduction test (Stitz & Schellekens, 1980) or in the reduction of a cytopathic effect. Moreover, a 50~o reduction in plaque formation is measurable with precision, while VSV was used because it replicates in many different cell species and is therefore widely used for detecting and standardizing antiviral activities of IFN. A working stock used for all experiments was prepared from the allantoic cavity of 10-day-old infected embryonated eggs. The plaquing efficiencies of this preparation of VSV differed little between cell species, and plaques formed within 48 h. Therefore, the assay using VSV as the challenge virus gave a true measure of the sensitivity of cells to IFN without being influenced by the virulence of the virus (Taguchi & Siddell, 1985) . Cell cultures were treated with IFN for 18 h and then infected with VSV. The procedure for the plaque assay has been described elsewhere (Horisberger & de Staritzky, 1985) . Fig. 1 illustrates the effect of the IFN-eB/D hybrid on plaque formation by VSV in several diploid cell cultures from different animal species. The IFN-c~B/D hybrid was active in all species tested with the exception of chicken ceils which were non-responsive. It was even more potent in some heterologous cell species than in the homologous human cells. The profile of cross-species activity has been compared with that of IFN-eF, and of the parent IFN-eB and -~D. The comparison was based on the IFN protein concentration (pg/ml) needed to cause a 50~o reduction of VSV plaque number in the different types of cell culture. The antiviral activity of recombinant HulFNs on 13 different cell species is presented in Table 1 and the salient points may be summarized as follows. The IFN-~B/D hybrid had the highest degree of cross-species specificity, and IFN-eF had the lowest. When both parent IFN-c~B and -eD showed activity in a cell species, the IFN-c~B/D hybrid had comparable or better activity than the more active parent. The IFN-c~B/D hybrid was effective on mouse, hamster and rat cells in contrast to IFNc~B which was almost inactive on these cell species. The IFN-c~B/D hybrid shared with IFN-eD a broad cross-species activity. However, the IFN-ccB/D hybrid had its own unique profile of activity because it was 10-, 30-and 50-fold more active than IFN-c~D on human, rabbit and mouse cells, respectively. Bovine cells did not discriminate between recombinant IFNs, in agreement with earlier results (Rehberg et al., 1982; Streuli et al., 1981 . Our results suggest that neither pig nor sheep cells discriminate between different species of recombinant human IFN-c~.
During the course of this study, it was observed that diploid cells at early passage in tissue culture were in general more susceptible to the antiviral action of IFN than established cell lines of the same species. Table 1 illustrates this observation for the equine dermis cell line (NBL-6) and for the pig kidney cell line PK-15. This may explain the relatively low activity of the human IFN-ctB/D hybrid on the established cell line of monkey Vero cells as compared to human diploid cells. However, the ovine choroid plexus cell line, an established cell line with a long history of subculture in vitro (Torchio & Trowbridge, 1977) , had not lost its sensitivity to human IFNs. The human recombinant IFNs had even greater activity on ovine cells than on homologous cells, in accordance with earlier results (Yilma, 1983) . IFN reacts with cells by binding to specific receptors present on the cell surface. This binding seems to be essential for IFN action (for review, see Sen, 1984) . The mechanism controlling the species specificity is most likely to depend on the affinity of the receptor for IFN. For instance, there is a direct correlation between the binding of recombinant human IFN and induction of its antiviral action on bovine and murine cells (Zoon et al., 1982; Aguet et al., 1984) . The receptor probably recognizes and binds a large portion of the IFN molecule. Therefore, it is difficult to attribute the role in the species specificity of an IFN-c~B/D hybrid to a particular segment of a parental IFN. The IFNctB/D hybrid most likely adopts a new conformation which is compatible with the receptors of a large variety of animal species. The elucidation of the three-dimensional structure of the IFNctB/D hybrid should help to resolve speculation concerning the interaction of the IFN-c~B/D hybrid with a multiplicity of species-specific IFN receptors.
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